Summary: In this secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial (N=2539 adults with obesity or overweight), all tirzepatide groups (5, 10 and 15 mg weekly) showed significant improvements in health-related quality of life versus placebo at week 72. A graded pattern was observed, with the largest gains in participants achieving at least 20% weight reduction (SF-36v2 Physical Component Summary +4.60; IWQOL-Lite-CT Total +24.7).
PICO Summary
| Element | Detail |
|---|---|
| Population | 2539 adults with obesity or overweight enrolled in the multicentre, double-blind, randomised SURMOUNT-1 trial (NCT04184622); this report is a prespecified secondary analysis of patient-reported outcomes. |
| Intervention | Subcutaneous tirzepatide 5, 10 or 15 mg once weekly for 72 weeks; PRO instruments were IWQOL-Lite-CT, SF-36v2 and EQ-5D-5L. |
| Comparison | Matching once-weekly placebo. A secondary, non-randomised within-trial comparison grouped participants by degree of weight reduction (greater than 0 to less than 5%, 5 to less than 10%, 10 to less than 20%, and at least 20%). |
| Outcome | All tirzepatide groups showed significant PRO improvement versus placebo. Improvement increased with greater weight reduction, becoming apparent from at least 5% loss. At week 72 the at least 20% weight-reduction group showed the greatest change from baseline: SF-36v2 Physical Component Summary +4.60, SF-36v2 Mental Component Summary +0.80, and IWQOL-Lite-CT Total +24.7. Participants with baseline physical or psychosocial limitations improved more than those without. The abstract reported point estimates without accompanying 95% confidence intervals or p values for the weight-category magnitudes; no ARR or NNT applies to these continuous outcomes. |
Tirzepatide weight loss and quality of life (SURMOUNT-1)
RCT secondary PRO analysis · obesity · 72 weeks
All tirzepatide doses improved patient-reported quality of life versus placebo, with the largest gains in those losing at least 20% of body weight. The dose-response by weight category is associational, not randomised.
Expert Commentary
This analysis supports the view that the weight reduction achieved with tirzepatide is accompanied by meaningful gains in how patients feel and function, not merely a change on the scale. Because the treatment-versus-placebo comparison is anchored in a randomised, double-blind design, the finding that all three doses improved patient-reported outcomes is reasonably robust. The graded relationship between greater weight loss and larger quality-of-life gains is biologically plausible and clinically reassuring, although it should be read with caution: the weight-category groupings are not randomised but are defined by response to treatment, so this dose-response signal is associational rather than causal, and healthier or more adherent participants may have driven both the weight loss and the reported benefit. A further limitation is that the analysis was conducted and largely authored by the manufacturer, Eli Lilly, and the abstract presented point estimates without confidence intervals or p values for the weight-category magnitudes, which constrains independent appraisal of precision. Can I use this with my patients? Yes, for adults with obesity who are candidates for tirzepatide, these data can be used to set realistic expectations that substantial weight loss is generally accompanied by improved physical function and well-being. Clinicians should temper enthusiasm by noting that gastrointestinal side effects are common and that the largest published gains were seen only at the highest categories of weight reduction. Independent, sponsor-neutral confirmation of the magnitude of these patient-reported benefits would be welcome.
References
Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, Ling Poon J. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(2):539-550. doi:10.1111/dom.16046